ArticleEndocrine2025
Increased survival reveals new paradigms in diabetic macular edema among patients with type 1 diabetes.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment and monitoring developments markedly improved the survival rate of individuals with type 1 diabetes (T1D). Nevertheless, literature remains scarce on long-term incidence of diabetic macular edema (DME) in this population, with the major study existing in the field - Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) - reporting its development at 30 years of disease. We aimed to estimate the long-term risk of DME and associated factors in a representative sample of type 1 diabetic patients.
methodsThis retrospective cohort study included 235 patients with T1D from a tertiary center in Portugal. Data on demographics and clinical characteristics were extracted from digital medical records and analyzed using descriptive statistics. Kaplan-Meier survival analysis was used to assess DME development over the follow-up period. Potential predictors of DME, including age at T1D diagnosis, duration of T1D, glycated hemoglobin (HbA1c), body mass index (BMI), severity of diabetic retinopathy (DR), systolic and diastolic blood pressure (SBP and DBP), and smoking habits, were analyzed using multivariate Cox regression.
resultsThe overall prevalence of DME was 18.7%. The cumulative risk of developing DME escalated from 7.6% at 20 years to 51.1% at 65 years of T1D duration (p < 0.001). Patients with severe or proliferative DR had a significantly higher prevalence of DME (p < 0.001). The prevalence of microvascular complications was higher in the DME group (54.5% versus 19.4%, p < 0.001). Age at T1D diagnosis and DR severity were the strongest predictors of DME, with hazard ratios of 1.03 (95% CI [1.00-1.06]; p = 0.029) and 1.46 (95% CI [1.20-1.77]; p < 0.001), respectively. HbA1c and SBP were associated with DME in univariate analysis but lost significance in multivariate models.
conclusionsThis study highlights the time-dependent nature of DME development in T1D, with a marked increase in risk beyond 20 years of disease duration, a pattern that appears to differ from what is typically observed in T2D. DR severity was a key predictor of DME. DME was associated with the presence of microvascular, but not macrovascular complications. These findings emphasize the importance of tailored surveillance strategies to improve outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.